Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 136, Issue 3, Pages 730-739Publisher
WILEY-BLACKWELL
DOI: 10.1002/ijc.29025
Keywords
dihydropyrimidine dehydrogenase gene; DPYD; fluoropyrimidine; 5-fluorouracil; capecitabine; drug safety; pharmacogenetics
Categories
Funding
- Swiss National Science Foundation [119839, 138285]
Ask authors/readers for more resources
We investigated the clinical relevance of dihydropyrimidine dehydrogenase gene (DPYD) variants to predict severe early-onset fluoropyrimidine (FP) toxicity, in particular of a recently discovered haplotype hapB3 and a linked deep intronic splice site mutation c.1129-5923C>G. Selected regions of DPYD were sequenced in prospectively collected germline DNA of 500 patients receiving FP-based chemotherapy. Associations of DPYD variants and haplotypes with hematologic, gastrointestinal, infectious, and dermatologic toxicity in therapy cycles 1-2 and resulting FP-dose interventions (dose reduction, therapy delay or cessation) were analyzed accounting for clinical and demographic covariates. Fifteen additional cases with toxicity-related therapy delay or cessation were retrospectively examined for risk variants. The association of c.1129-5923C>G/hapB3 (4.6% carrier frequency) with severe toxicity was replicated in an independent prospective cohort. Overall, c.1129-5923G/hapB3 carriers showed a relative risk of 3.74 (RR, 95% CI=2.30-6.09, p=2 x 10(-5)) for severe toxicity (grades 3-5). Of 31 risk variant carriers (c.1129-5923C>G/hapB3, c.1679T>G, c.1905+1G>A or c.2846A>T), 11 (all with c.1129-5923C>G/hapB3) experienced severe toxicity (15% of 72 cases, RR=2.73, 95% CI=1.61-4.63, p=5 x 10(-6)), and 16 carriers (55%) required FP-dose interventions. Seven of the 15 (47%) retrospective cases carried a risk variant. The c.1129-5923C>G/hapB3 variant is a major contributor to severe early-onset FP toxicity in Caucasian patients. This variant may substantially improve the identification of patients at risk of FP toxicity compared to established DPYD risk variants (c.1905+1G>A, c.1679T>G and c.2846A>T). Pre-therapeutic DPYD testing may prevent 20-30% of life-threatening or lethal episodes of FP toxicity in Caucasian patients. What's New? Fluorouracil (5FU) is effective against a variety of cancers and is one of the most commonly prescribed chemotherapy drugs. But 5FU causes severe toxicity in some patients, with their susceptibility determined largely by variations in the rate-limiting enzyme dihydropyrimidine dehydrogenase (DPD), which catabolizes 5FU. This study shows that a relatively common haplotype, hapB3, which is linked to an intronic splice site mutation (c.1129-5923C>G) in the DPD-encoding gene, DPYD, is a major contributor to early-onset severe fluoropyrimidine toxicity in Caucasian carriers. Inclusion of the c.1129-5923C>G variant in DPYD genetic testing could help prevent severe toxicity associated with fluoropyrimidine-based therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available